ERBB2 and gastroesophageal junction adenocarcinoma: In summary, we used an ultra-sensitive, tumor-informed ctDNA assay to investigate the role of ctDNA as a biomarker of survival, response, and progression in patients with metastatic HER2-negative esophagogastric adenocarcinoma treated with pembrolizumab and chemotherapy in the KeyLargo study.